Abstract:
CMV is the most frequent congenital infection and has a UK incidence of around 3-4/1000 live births. Around 10-15% of these infants will be symptomatic, of whom up to 90% will develop long term sequelae usually in the form of sensorineural hearing loss, visual impairment, or developmental delay. Some 13% of asymptomatic infants also develop long term problems. Despite such morbidity, decisions of whom to treat, and for how long, remain controversial.
Audience Take Away
- Objectives of session: Whilst there is some support for treating infants with CNS symptoms, there is a paucity of high-level evidence for treating infants with other organ involvement
- In addition, the adverse effects of treatment are not inconsiderable
- Thus the talk will aim to address these dilemmas and help the participants develop an evidence-based management approach